Ivey Publishing
Changsheng Bio-Technology Co. Ltd. (China): Fallout from the Vaccines Scandal
Product Number:
9B19C027
Publication Date:
09/27/2019
Revised Date:
09/27/2019
Length:
9 pages (6 pages of text)
Product Type:
Case (Pub Mat)
Source:
Ivey/NUS
In 2018, Changsheng Bio-technology Co., Ltd. (Changsheng), a leading biopharmaceutical company and one of the market leaders in vaccines, was found to have falsified its production and inspection data and to have sold substandard vaccines in the Chinese market. The unethical conduct triggered widespread public anger and immediate government intervention. What actions could Changsheng take to mitigate the effect of this scandal?
Learning Objective:
This case study is suitable for an undergraduate- or graduate-level course on business ethics in emerging economies, organizational behaviour, or corporate social responsibility. After working through the case and assignment questions, students will be able to do the following:
  • Understand the complexity and contributing factors behind the scandal and describe the roles of various players: Changsheng, the Chinese government, and social media.
  • Propose strategies to counteract and mitigate the effects of unethical conduct.
  • Recommend what actions could have been taken to prevent the wrongdoing and to enhance quality control in the production line, given the high complexity of and lack of transparency in the situation.
Issues:
Disciplines:
Organizational Behaviour/Leadership,  International
Industries:
Health Care Services
Setting:
China; China, Medium, 2018
Intended Audience:
Undergraduate/MBA
Price:
$4.25 CAD / $4.25 USD Printed Copy
$3.75 CAD / $3.75 USD Permissions
$3.75 CAD / $3.75 USD Digital Download
You Might Also Like...

Save In: